CHICAGO — A Fas inhibitor showed strong efficacy signals and demonstrated in patients with more than 8 days of macula-off rhegmatogenous retinal detachment, according to a study. A Fas inhibitor ...

ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal ...

ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal ...

ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal ...

ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal ...

KUALA LUMPUR, Oct 10 (Bernama) -- Individuals aged 40 and above, particularly those with high myopia (nearsightedness), a history of eye injury, or who have undergone eye surgery, are at a higher risk ...